Lipolanthionine peptides act as inhibitors of TLR2-mediated IL-8 secretion. Synthesis and structure-activity relationships

Journal of Medicinal Chemistry

Volumn 49, Issue 5, 2006, Pages 1754-1765

  Seybert, Tobias ^a   Voss, Söhnke ^a   Brock, Roland ^a   Wiesmüller, Karl Heinz ^b   Jung, Günther ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b EMC MICROCOLLECTIONS GMBH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT; AMINE; FATTY ACID; IMMUNOLOGIC AGENT; INTERLEUKIN 8; LIPOLANTHIONINE PEPTIDE; SULFUR; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 6; UNCLASSIFIED DRUG; VACCINE;

ARTICLE; CELL ACTIVATION; CHIRALITY; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG ACTIVITY; DRUG SYNTHESIS; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; HUMAN CELL; IMMUNE SYSTEM; MYCOPLASMA; OXIDATION; STRUCTURE ACTIVITY RELATION;

ADJUVANTS, IMMUNOLOGIC; ALANINE; CELL LINE; FATTY ACIDS; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; INTERLEUKIN-8; MAGNETIC RESONANCE SPECTROSCOPY; OLIGOPEPTIDES; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; SULFIDES; TOLL-LIKE RECEPTOR 2;

EID: 33644858135     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm050585d     Document Type: Article

References (52)

1. Braun. V. Covalent lipoprotein from the outer membrane of Escherichia coli. Biochim. Biophys. Acta 1975, 415, 335-377.
2. Braun, V.; Wu, H. C. Lipoproteins, structure, function, biosynthesis and model for protein export. In Comprehensive Biochemistry, Bacterial Cell Wall. 27; Ghuysen, J. M., Hakenback, R., Eds.; Elsevier: Amsterdam, 1993; 319-342.
3. Mühlradt, P. F.; Kiess, M.; Meyer, H.; Süssmuth, R.; Jung. G. Structure and specific activity of macrophage-stimulating lipopeptides from Mycoplasma hyorhinis. Infect, Immunol. 1998, 66, 4804-4810.
4. Miihlradt, P. F.; Kiess, M.; Meyer, H.; Süssmuth, R.; Jung, G. Isolation, structure elucidation, and synthesis of a macrophage stimulatory lipopeptide from Mycoplasma fermentans acting at pico molar concentration. J. Exp. Med. 1997, 185, 1951-1958.
5. Metzger, J.; Wiesmüller, K.-H.; Schaude, R.; Bessler, W.; Jung, G. Synthesis of novel immunologically active tripalmitoyl-S-glyceryl-cysteinyl lipopeptides as useful intermediates for immunogen preparations. Int. J. Pept. Protein Res. 1991, 37, 46-57.
6. Wiesmüller, K.-H.; Jung, G.; Hess, G. Novel low-molecular weight synthetic vaccine against foot-and-mouth disease containing a potent B-cell and macrophage activator. Vaccine 1989, 7, 29-33.
7. Wiesmüller, K.-H.; Bessler, W. G.; Jung, G. Solid-phase peptide synthesis of lipopeptide vaccines eliciting epitope-specific B-, T-helper and T-killer cell response. Int. J. Pept. Protein Res. 1992, 40, 255-260.
8. Deres, K.; Schild, H. J.; Wiesmüller, K.-H.; Jung, G.; Rammensee. H.-G. In vivo priming of virus specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine. Nature 1989, 342, 561-564.
9. Schild, H.; Deres, K.; Wiesmüller, K.-H.; Jung, G.; Rammensee, H.-G. Efficiency of peptides and lipopeptides for in vivo priming of virus-specific cytotoxic T cells. Eur. J. Immunol. 1991, 21, 2649-2654.
10. Wiesmüller, K.-H.; Fleckenstein, B.; Jung, G. Peptide vaccines and peptide libraries. Biol. Chem. 2001, 382, 571-579.
11. Janeway, C. A., Jr.; Medzhitov, R. Innate immune recognition. Anna. Rev. Immunol. 2002, 197-216.
12. Akira, S.; Takeda, K. Toll-like receptor signaling. Nature Rev. Immun. 2004, 4, 499-511.
13. Schnare, M.; Barton, G. M.; Holt, A. C.; Takeda, K.; Akira, S.; Medzhitov, R. Toll-like receptors control activation of adaptive immune responses. Nature Immunol. 2001, 2, 947-950.
14. Tsunoda, I.; Sette, A.; Fujinami, R. S.; Oseroff, C.; Ruppert, J.; Dahlberg, C.; Southwood, S.; Arrhenius, T.; Kuang, L. Q.; Kubo, R. T.; Chesnut, R. W.; Ishioka, G. Y. Lipopeptide panicles as the immunologically active component of CTL inducing vaccines. Vaccine 1999, 17, 675-685.
15. Sieling, P. A.; Chung, W.; Duong, B. T.; Godowski, P. J.; Modlin, R. L. Toll-like receptor 2 ligands as adjuvants for human ThI responses. J. Immunol. 2003, 170, 194-200.
16. Spohn, R.; Buwitt-Beckmann, U.; Brock, R.; Jung, G.; Ulmer, A. J.; Wiesmüller, K.-H. Synthetic lipopeptide adjuvants and Toll-like receptor 1-structure-activity relationships. Vaccine 2004, 22, 2494-2499.
17. Müller, S. D. C.; Müller, M. R.; Huber, M.; van der Esche, U.; Kirschning, C. J.; Wagner, H.; Bessler, W. G.; Mittenbühler, K. Triacyl-lipopentapeptide adjuvants: TLR2-dependent activation of macrophages and modulation of receptor-mediated cell activation by altering acyl-moieties. Int. Immunopharm. 2004, 4, 1287-1300.
18. Metzger, J.; Jung, G.; Bessler, W. G.; Hoffmann, P.; Strecker, M.; Lieberknecht, A.; Schmidt, U. Lipopeptides containing 2-palmitoyl-amino-6,7- bis(palmitoyloxy)-heptanoic acid: Synthesis, stereospecific Stimulation of B-lymphocytes and macrophages, adjuvanticity in vivo and in vitro. J. Med. Chem. 1991, 34, 1969-1974.
19. Schmidt, U.; Lieberknecht, A.; Kazmaier, U.; Griesser, H.; Jung, G.; Metzger, J. Amino Acids and Peptides; 73. Synthesis of di- and trihydroxy-amino acids-Construction of lipophilic tripalmitoyldi-hydroxy-a-amino acids. Synthesis 2001, 49-56.
20. Zuany-Amorim, C.; Hastewell, J.; Walker, C. Toll-like receptory as potential therapeutic targets for multiple diseases. Nature Rev. Drug. Discuss. 2002, 1, 797-807.
21. Meng, G.; Rutz, M.; Schiemann, M.; Metzger, J.; Grabiec, A.; Schwandner, R.; Luppa, P. B.; Ebel, F.; Busch, D. H.; Bauer, S.; Wagner, H.; Kirschning, C. J. Antagonistic antibody prevents toll-like receptor 2-driven lethal shock-like syndromes. J. Clin. Invest. 2004, 113, 1473-1481.
22. Jung, G. Lantibiotics-ribosomally synthesized biologically active polypeptides containing sulfide bridges and α,β-didehydroamino acids. Angew. Chem., Int. Ed. 1991, 30, 1051-1068.
23. Jung, G. Lantibiotics: A survey. In Nisin and Novel Lantibiotics: Jung, G., Sahl, H. G., Eds.; ESCOM: Leiden, 1991; pp 1-34.
24. Süssmuth, R. D.; Jack, R. W.; Jung, G. Lanthionine Peptides. In Synthesis of Peptides and Peptidomimetics (Houben-Weyl); Goodman, M., Felix, A., Moroder, L., Toniolo, C., Eds.; Thieme: Stuttgart, 2003; Vol. E 22b, pp 184-213.
25. Brown, G.; du Vigneaud, V. The stereoisomeric forms of lanthionine. J. Biol. Chem. 1941, 140, 161-771.
26. Probert, J. M.; Rennex, D.; Bradley, M. Lanthionines for solid-phase synthesis. Tetrahedron Lett. 1996, 37, 1101-1104.
27. Shao, H.; Wang, S. H. H.; Lee, C. W.; Ösapay, G.; Goodman, M. A facile synthesis of orthogonally protected stereoisomeric lanthionines by regioselective ring opening of serine β-lactones. J. Org. Chem. 1995, 60, 2956-2957.
28. Ösapay, G.; Prokai, L.; Kim, H. S.; Medzihradszky, K. F.; Coy, D. H.; Liapakis, G.; Reisine, T.; Melacini, G.; Zhu, Q.; Wang, S. H. H.; Mattern, R. H.; Goodman, M. Lanthionine-somatostatin analogs: Synthesis, characterization, biological activity, and enzymatic stability studies. J. Med. Chem. 1997, 40, 2241-2251.
29. Cavelier-Frontin, F.; Daunis, J.; Jacquier, R. New diastereoselective synthesis of protected meso-lanthionine with discrimination of the chiral centers. Tetrahedron Asymmetry 1992, 3, 85-94.
30. Dugave, C.; Menez, A. Synthesis of natural and non natural orthogonally protected lanthionines from N-tritylserine and allothreonine derivatives. Tetrahedron Asymmetry 1997, 8, 1453-1465.
31. Jobron, L.; Hummel, G. Solid-phase synthesis of new S-glycoamino acid building blocks. Org. Lett. 2000, 2, 2265-2267.
32. Gair, S.; Jackson, R. F. W.; Brown, P. A. Stereoselective synthesis of all stereoisomeric 2-amino-3-hydroxy-4-phenylbutanolides. Tetrahedron Lett. 1997, 38, 3059-3062.
33. Mustapa, M. F. M.; Harris, R.; Bulic-Subanovic, N.; Elliott, S. L.; Bregant, S.; Groussier, M. F. A.; Mould, J.; Schultz, D.; Chubb, N. A. L.; Gaffney, P. R. J.; Driscoll, P. C.; Tabor, A. B. Synthesis of orthogonally protected lanthionines. J. Org. Chem. 2003, 68, 8185-8192.
34. Mustapa, M. F. M.; Harris, R.; Esposito, D.; Chubb, N. A. L.; Mould, J.; Schultz, D.; Driscoll, P. C.; Tabor, A. B. Synthesis of a cyclic peptide containing norlanthionine: Effect of the thioether bridge on peptide conformation. J. Org. Chem. 2003, 68, 8193-8198.
35. Zhu, X. M.; Schmidt, R. R. Efficient synthesis of differently protected lanthionines via beta-bromoalanine derivatives. Ear. J. Org. Chem. 2003, 4069-4072.
36. Wiesmüller, K.-H.; Bessler, W.; Jung, G. Synthesis of the mitogenic S-[2,3-bis(palmitoyloxy)propyl]-N-palmitoylpentapeptide from Escherichia coli lipoprotein. Hoppe-Seyler's Z. Physiol. Chem. 1983, 364, 593-606.
37. Schultz, M.; Kunz, H. Synthetic O-glycopeptides as model substrates for glycosyltransferases. Tetrahedron: Asymmetry 1993, 4, 1205-1220.
38. Miller, M. J. Isourea-mediated preparation of dehydro amino acids. J. Org. Chem. 1980, 45, 3131-3132.
39. Kuesters, E.; Allgaier, H.; Jung, G.; Bayer, E. Resolution of sulfurcontaining amino acids by chiral phase gas chromatography. Chromatographia 1984, 18, 287-293.
40. Kaiser, E.; Colescott, R. L.; Bossinger, C. D.; Cook, P. I. Color test for detection of free terminal amino groups in the solid-phase synthesis of peptides. Anal. Biochem. 1970, 34, 595-598.
41. Matteucci, M.; Bhalay, G.; Bradley, M. Cystine mimetics-Solid-phase lanthionine synthesis. Tetrahedron Lett. 2004, 45, 1399-1401.
42. Mata, E. G. β-Lactams on solid support: Mild and efficient removal of penicillin derivatives from Merrifield resin using aluminium chloride. Tetrahedron Lett. 1997, 38, 6335-6338.
43. Wiesmüller, K.-H.; Hess, G.; Bessler, W. G.; Jung, G. Diastereomers of tripalmitoyl-S-glyceryl-1-cysteinyl carrier adjuvant systems induce different mitogenic and protective immune response. In Chirality and Biological Activity; Homstedt, B., Frank, H., Testa, B., Eds.; Alan R. Liss: New York, 1990; pp 267-272.
44. Reichel, F.; Roelofsen, A. M.; Geurts, H. P. M.; Hämälä inen, T. I.; Feiters, M. C.; Boons, G.-J. Stereochemical dependence of the self-assembly of the immunoadjuvants Pam3Cys and Pam3Cys-Ser. J. Am. Chem. Soc: 1999, 121, 7989-7997.
45. Kurimura, M.; Takemoto, M.; Achiwa, K. Synthesis of optically active lipopeptide analogues from the outer membrane of Excherichia coli. Chem. Pharm. Bull. 1991, 39, 1590-2596.
46. Rustici, A.; Velucchi, M.; Faggioni, R.; Sironi, M.; Ghezzi, P.; Quataert, S.; Green, B.; Porro, M. Molecular mapping and detoxification of the lipid A binding site by synthetic peptides. Science 1993, 259, 361-365.
47. Triantafilou, M.; Miyake, K.; Golenbock, D. T.; Triantafilou, K. Mediators of innate immune recognition of bacteria concentrate in lipid rafts and facilitate lipopolysaccharide-induced cell activation. J. Cell Science 2002, 115, 2603-2611.
48. Pfeiffer, A.; Böttcher, A.; Orso, E.; Kapinsky, M.; Nagy, P.; Bodnar, A.; Spreitzer, I.; Liebisch, G.; Drobnik, W.; Gempel, K.; Horn, M.; Holmer, S.; Hartung, T.; Multhoff, G.; Schutz, G.; Schindler, H.; Ulmer, A. J.; Heine, H.; Stelter, F.; Schutt, C.; Rothe, G.; Szollosi, J.; Damjanovich, S.; Schmilz, G. Lipopolysaccharide and ceramide docking to CD14 provokes ligand-specific receptor clustering in rafts. Eur. J. Immunol. 31, 3153-3164.
49. Walton, K. A.; Cole, A. L.; Yeh, M.; Subbanagounder, G.; Krutzik, S. R.; Modlin, R. L.; Lucas, R. M.; Nakai, J.; Smart, E. J.; Vora, D. K.; Berliner, J. A. Specific phospholipid oxidation products inhibit ligand activation of toll-like receptors 4 and 2. Arterioscler. Thromb. Vasc. Biol. 2003, 23, 1197-1203.
50. Stulnig, T. M.; Huber, J.; Leitinger, N.; Imre, E. M.; Angelisova, P.; Nowotny, P.; Waldhausl, W. Polyunsaturated eicosapentaenoic acid displaces proteins from membrane rafts by altering raft lipid composition. J. Biol. Chem. 2001, 276, 37335-37340.
51. Zeyda, M.; Staffier, G.; Horejsi, V.; Waldhausl, W.; Stulnig, T. M. LAT displacement from lipid rafts as a molecular mechanism for the inhibition of T cell signaling by polyunsaturated fatty acids. J. Biol. Chem. 2002, 277, 28418-28423.
52. Manukyan, M.; Triantafilou, K.; Triantafilou, M.; Mackie, A.; Nilsen, N.; Espevik, T.; Wiesmueller, K. H.; Ulmer, A. J.; Heine, H. Binding of lipopeptide to CD14 induces physical proximity of CD14, TLR2 and TLR1. Eur. J. Immunol. 2005, 35, 911-921.